Dillon & Associates Inc Biogen Inc. Transaction History

Dillon & Associates Inc

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$236.26 - $355.63 $243,584 - $366,654	-1,031 Closed	0 $0
Q3 2020 Nov 06, 2020	SELL	$264.77 - $305.71 $84,726 - $97,827	-320 Reduced 23.69%	1,031 $293,000
Q1 2020 May 07, 2020	SELL	$268.85 - $341.04 $26,885 - $34,104	-100 Reduced 6.89%	1,351 $427,000
Q4 2019 Feb 03, 2020	SELL	$220.06 - $304.07 $93,525 - $129,229	-425 Reduced 22.65%	1,451 $431,000
Q3 2019 Oct 25, 2019	SELL	$217.44 - $243.88 $202,219 - $226,808	-930 Reduced 33.14%	1,876 $437,000
Q2 2019 Jul 22, 2019	SELL	$219.29 - $241.72 $13,157 - $14,503	-60 Reduced 2.09%	2,806 $657,000
Q1 2019 May 07, 2019	BUY	$216.71 - $338.96 $9,751 - $15,253	45 Added 1.6%	2,866 $676,000
Q4 2018 Feb 14, 2019	BUY	$278.5 - $352.75 $29,242 - $37,038	105 Added 3.87%	2,821 $849,000
Q3 2018 Nov 14, 2018	BUY	$293.51 - $383.83 $27,883 - $36,463	95 Added 3.62%	2,716 $959,000
Q2 2018 Aug 08, 2018	BUY	$257.52 - $306.91 $102,235 - $121,843	397 Added 17.85%	2,621 $760,000
Q1 2018 May 08, 2018	BUY	$260.13 - $367.91 $148,013 - $209,340	569 Added 34.38%	2,224 $609,000
Q4 2017 Feb 08, 2018	BUY	$307.64 - $344.58 $56,913 - $63,747	185 Added 12.59%	1,655 $528,000
Q3 2017 Nov 13, 2017	BUY	$281.15 - $329.69 $2,811 - $3,296	10 Added 0.68%	1,470 $460,000
Q2 2017 Aug 09, 2017	BUY	N/A	1,460	1,460 $396,000

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.6B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Dillon & Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Dillon & Associates Inc with notifications on news.